RNAConnect today announced the commercial launch of the UltraMarathonRT® (uMRT) cDNA Synthesis and Amplification Kit, a next-generation tool designed to significantly advance short-read RNA sequencing. Leveraging the ultra-processive power of a group II intron reverse transcriptase with intrinsic helicase activity, the kit enables researchers to achieve unprecedented sensitivity, capturing even rare isoforms, long noncoding RNAs, and structurally complex transcripts that often escape detection with standard retroviral enzymes.
Science Significance
The UltraMarathonRT kit represents a major technical leap in transcriptomics, solving one of the longest-standing bottlenecks in RNA-seq: incomplete cDNA synthesis. Traditional retroviral reverse transcriptases frequently stall or detach when copying long or structured RNAs, creating blind spots in sequencing data. By contrast, uMRT’s processivity allows full-length cDNA synthesis in a single pass, unlocking deeper insights into transcriptional complexity, splicing, and intron retention.
Regulatory Significance
While classified as a research-use-only (RUO) reagent, UltraMarathonRT may shape future regulatory-grade transcriptomic assays. By enabling more accurate RNA representation, the kit could inform the development of validated workflows for biomarker discovery, clinical genomics, and eventually laboratory-developed tests (LDTs) or regulated diagnostics. Its high fidelity and reproducibility may position it as a candidate for bridging RUO to translational and clinical applications in regulatory pathways.
Business Significance
Advertisement
The launch extends RNAConnect’s competitive footprint in the fast-growing RNA analysis tools market, estimated to exceed $5 billion globally. UltraMarathonRT is available in flexible kit sizes to serve both small labs and high-throughput core facilities, with OEM and bulk supply options targeting industrial-scale users. By offering a drop-in replacement for Illumina®-style workflows, the kit lowers adoption barriers and positions RNAConnect as a disruptive player in transcriptomics innovation.
Patients’ Significance
Though not a therapeutic product, UltraMarathonRT has downstream implications for patients living with cancer, neurodegenerative disease, and rare genetic disorders, where transcript-level resolution is key to biomarker discovery and therapeutic development. By enabling researchers to detect rare isoforms and regulatory RNAs with higher fidelity, the technology may accelerate the discovery of precision medicine targets and improve diagnostic sensitivity in future clinical applications.
Policy Significance
The commercial availability of UltraMarathonRT highlights the importance of policy frameworks supporting advanced molecular research tools, particularly those that bridge RUO technologies into translational research. As regulatory agencies and funding bodies push for greater reproducibility and data completeness in genomics, tools like UltraMarathonRT will be essential for meeting evolving standards in precision medicine and genomic research policy.
Transaction Highlights
RNAConnect, based in Branford, CT, has launched the UltraMarathonRT® cDNA Synthesis & Amplification Kit, a next-generation solution designed to enhance short-read RNA sequencing applications including transcriptomics, biomarker discovery, isoform mapping, and intron retention analysis. Powered by an ultra-processive group II intron reverse transcriptase with intrinsic helicase activity, the kit enables improved full-length cDNA synthesis, delivering superior quantification of long and structurally complex RNAs while maintaining seamless compatibility with standard Illumina® workflows. Now commercially available worldwide, UltraMarathonRT is offered in flexible kit sizes ranging from pilot studies to high-throughput projects, with OEM and bulk packaging options available for large-scale and core facility users.
Source: RNA Connect Press Release
